EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent -
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Ajay Kirtane, EVOLVE SHORT DAPT WEB - Cardiovascular News
Session evaluation and key learnings
Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
Three-month DAPT after PCI with Synergy stent supported in EVOLVE Short DAPT trial - Cardiovascular News
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
EVOLVE Short DAPT
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk | NEJM
For the FITs | Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI - American College of Cardiology
Complex Coronary Cases - ppt download
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
XIENCE Stent: Protecting Patients with Short DAPT Needs | Abbott
Another Coronary Stent for Patients at High Bleeding Risk∗ | JACC: Cardiovascular Interventions
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy - ScienceDirect
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
31861-1.fp.png "SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal")
SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal
